Close Menu


News and reporting on cancer immunotherapy.

The company reported $112.4 million in revenues compared to $83.2 million in Q4 2019, beating the average Wall Street estimate of $106.6 million.

In PNAS this week: immunotherapy for hard-to-treat breast cancers, effects of oncogenic histone H3K36M mutations, and more.

A new study lends credence to the idea that pre-existing anti-cancer immunity depends heavily on patients' genetic background, according to one of the researchers.

A small study suggests fecal transplants could increase the number of cancer patients who respond to immunotherapy, according to LiveScience.

The move will add Chronix's proprietary technology for blood-based immune therapy monitoring and transplant rejection testing to Oncocyte's existing test menu.

The Phase II trial will use OmniSeq's RNA-seq assay to determine whether patients should be treated with one of two agents combined with BMS' nivolumab.

The company's two largest investors will purchase $25 million of its common shares, with proceeds supporting ongoing test commercialization.

The Dutch bioinformatics firm's ImmunoGenomiX technology platform is helping researchers develop therapies for COVID-19 as well as for cancer.

Early data around an initial composite assay showed it can predict immunooncology drug responses more accurately than tumor mutational burden.

The B44 supertype is associated with improved survival in melanoma patients treated with immunotherapy, but less so in NSCLC patients, due to mutational differences.


Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.

Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.

Science reports that a Dutch research funding agency is combating a ransomware attack.

In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.